MENU
Showcases Stock ranks Forex

Zentalis Pharmaceuticals Inc (ZNTL)
15.76  0.57 (3.75%) 03-28 16:00
Open: 15.28 Pre. Close: 15.19
High: 16.075 Low: 15.22
Volume: 579,811 Market Cap: 1,118(M)
Stock Technical Analysis
Overall:     
Target: Six months: 21.11
One year: 24.65
Support: Support1: 15.03
Support2: 13.15
Resistance: Resistance1: 18.07
Resistance2: 21.11
Pivot: 14.36
Moving Averages: MA(5): 14.45
MA(20): 14.44
MA(100): 13.25
MA(250): 19.45
MACD: MACD(12,26): 0.25
Signal(12,26,9): 0.19
%K %D: %K(14,3): 66.19
%D(3): 43.64
RSI: RSI(14): 62.87
52-Week: High: 31.46
Low: 9.56
Change(%): -5.2
Average Vol(K): 3-Month: 824
10-Days: 742
Prices Prediction (Update @5:00pm)
If tomorrow: Open lower Open higher
High: 16.104 - 16.169 16.169 - 16.236
Low: 15.066 - 15.131 15.131 - 15.198
Close: 15.651 - 15.766 15.766 - 15.886
Price, MAs and Bollinger Bands
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.

[ ZNTL ] has closed below upper band by 0.7%. Bollinger Bands are 36.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
Company profile
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker. The company's other lead product candidate includes ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer. In addition, it is involved in developing ZN-d5, a selective inhibitor of B-cell lymphoma 2 that is in a Phase 1 clinical trial for the treatment of non-Hodgkin's lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, which is in Phase 1/2 clinical trial for the treatment of advanced non-small cell lung cancer. Further, the company is developing BCL-xL heterobifunctional degraders based on E3 ligases not expressed in platelets, allowing for the avoidance of dose-limiting thrombocytopenia associated with BCL-xL inhibitors. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Mayo Foundation for Medical Education and Research; SciClone Pharmaceuticals International (Cayman) Development Ltd.; Pfizer, Inc.; Eli Lilly and Company; GlaxoSmithKline, and Zentera Therapeutics (Cayman), Ltd. The company was incorporated in 2014 and is based in New York, New York.
Stock chart
Stock News
Thu, 28 Mar 2024
SG Americas Securities LLC Acquires 6252 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World

Tue, 26 Mar 2024
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Shares Up 4.8% - MarketBeat

Mon, 25 Mar 2024
Will Zentalis Pharmaceuticals Inc (ZNTL) Stay at the Top of the Healthcare Sector? - InvestorsObserver

Sun, 24 Mar 2024
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives $38.57 Average PT from Brokerages - MarketBeat

Sun, 24 Mar 2024
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World

Fri, 01 Mar 2024
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Financial Analysis
Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Underperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Exchange:  NASDAQ Global Market
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 70.96
Shares Float (M) 50.39
% Held by Insiders 4.22
% Held by Institutions 114.89
Shares Short (K) 14560
Shares Short Prior Month (K) 13670
Stock Financials
EPS -4.470
Book Value (p.s.) 6.180
Profit Margin
Operating Margin
Return on Assets (ttm) -28.5
Return on Equity (ttm) -67.1
Qtrly Rev. Growth
Gross Profit (p.s.)
Sales Per Share
EBITDA (p.s.) -3.489
Qtrly Earnings Growth
Operating Cash Flow (M) -207.82
Levered Free Cash Flow (M) -86.97
Stock Valuation
PE Ratio -3.53
PEG Ratio
Price to Book value 2.55
Price to Sales
Price to Cash Flow -5.38
Stock Dividends
Dividend
Dividend Yield
Dividend Growth

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android